Iterum Therapeutics Shares Key Findings at IDWeek 2024 Event
Iterum Therapeutics Reveals Essential Data at IDWeek 2024
Iterum Therapeutics plc (Nasdaq: ITRM), a leading pharmaceutical company from Dublin and Chicago, is dedicated to developing advanced antibiotics to tackle the growing issue of multi-drug resistant pathogens. They recently announced that they will present innovative data at the IDWeek 2024 conference, a significant event for the field of infectious diseases.
What Will Be Presented
During this prestigious conference, which takes place in Los Angeles, the company will showcase three pivotal posters that highlight their latest research and findings.
Study on Oral Sulopenem/probenecid
One of the key presentations is titled "Oral Sulopenem/probenecid for Uncomplicated Urinary Tract Infections (uUTI): Results from the REASSURE Trial." This study, presented by Steven I. Aronin, MD, will delve into new insights regarding a promising treatment option for urinary tract infections. It is scheduled for October 18, from 12:15 p.m. to 1:30 p.m., which reflects the commitment of Iterum Therapeutics to address common yet serious infections.
Analysis of Asymptomatic Bacteriuria
Another important piece of research being presented is "Asymptomatic Bacteriuria Not a Predictor of Clinical Failure in Uncomplicated Urinary Tract Infections (uUTI): A Prospective Analysis of Women Treated for uUTI from the REASSURE Trial." Dr. Aronin will also lead this presentation, showcasing an in-depth analysis that will provide valuable information on treatment outcomes, scheduled for a rapid fire format on October 18.
Sulopenem's Efficacy in Inhalational Anthrax
The final featured presentation is titled "Sulopenem is Efficacious in a Rabbit Model of Inhalational Anthrax." This study will highlight Sulopenem's effectiveness in an area of great concern, marking a significant addition to the knowledge base in treating severe bacterial infections.
Access to Poster Information
All of the information regarding these presentations will be made publicly available on the company’s website. After the conclusion of the conference, interested parties can visit the "Posters & Presentations" section under the “Our Science” tab to access the posters and learn more about the findings.
About Iterum Therapeutics plc
Iterum Therapeutics plc is on the forefront of combatting the critical challenge posed by multi-drug resistant pathogens. With their primary focus on developing anti-infective therapies, Iterum is advancing its main compound, sulopenem, which exists in both oral and IV formulations. This novel penem anti-infective has shown remarkable effectiveness against various gram-negative and gram-positive bacteria, showcasing powerful activity even against strains resistant to other treatments.
The company has actively submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for the oral formulation of sulopenem targeted at uncomplicated urinary tract infections, marking a significant step forward in providing viable treatment options. Moreover, sulopenem has received esteemed designations such as Qualified Infectious Disease Product (QIDP) and Fast Track status in several indications.
Investor Relations
For inquiries, Judy Matthews, Chief Financial Officer, can be reached at 312-778-6073 or via email.
Frequently Asked Questions
1. What is the primary focus of Iterum Therapeutics?
Iterum Therapeutics focuses on developing next-generation antibiotics to tackle multi-drug resistant infections.
2. When is IDWeek 2024 scheduled?
IDWeek 2024 is scheduled for October 16-19.
3. Who is presenting the research at the conference?
Dr. Steven I. Aronin is presenting the key research findings at IDWeek 2024.
4. What is Sulopenem?
Sulopenem is Iterum's leading anti-infective compound that targets various bacterial infections.
5. How can I find the posters presented at the conference?
The posters will be accessible on Iterum Therapeutics' website post-conference under the “Our Science” section.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Future Rate Cuts Expected as Economy Shows Resilience
- Tony Wehner Acquires Stock Options at Dave & Buster's Enter
- Antonio Pineiro's Strategic Stock Option Purchase at Dave & Buster's
- Insider Trading Insights: George J Christ's Recent Sale of Shares
- Understanding Insider Activity at Altair Engineering - ALTR
- Significant Insider Sale: Powell Industries' Thomas W Powell Moves Shares
- Keysight Launches Innovative 800GE Testing System for AI
- Integral Ad Science CFO Shares Insights From Recent Stock Moves
- Gigi Pip and Two Roads Hat Co. Set to Debut in Nashville
- AuthenticID Earns 2024 Honor as Top Fraud Prevention Provider
Recent Articles
- Examining September's Inflation Trends and Jobless Claims Rise
- Aprea Therapeutics Showcases Cutting-Edge Oncology Research
- TKO Group Holdings Set to Release Q3 Financial Insights
- Transforming Senior Housing Analysis with Engrain Partnership
- Trinity Capital Invests $40 Million in Beam Benefits Growth
- Hayward Holdings Announces Exciting Third Quarter Earnings Date
- Alpha Tau's Innovative Cancer Treatment Advances With First Patient
- Yakira Capital Calls for Fair Negotiations from Territorial Bancorp
- Marco Fregenal Wins Vanguard Award, Elevating Fathom Holdings
- Endeavor Group Holdings Set to Release Q3 Financial Results
- Cengage Work Report Highlights Successful Learning Outcomes
- Montana Technologies Enhances Commitment to Sustainable Water Solutions
- FM:Systems Unveils NetZero Advisor Integration for Sustainability
- ExxonMobil's Major Carbon Storage Initiative Enhances Energy Future
- LightPath Technologies Engages at AUSA 2024 for Defense Innovation
- cBrain's Rapid F2 Implementation for New Ministries in Denmark
- Grupo Bimbo: A Leader in Employee Satisfaction and Well-being
- Dobbs Tire & Auto Centers Strengthens Presence with ASC Deal
- Massimo Group Unveils New T-Boss UTV Series for Winter Use
- Nasdaq Ranks 5th in Global RiskTech100 Following Tech Division Launch
- Exciting Progress in Lipocine's Oral Brexanolone Development
- Global Expansion of Perfect Moment's Resale Program Launches
- Antiques at 112 and Old York Cellars: A Perfect Pairing
- Eaton and Lunar Energy Partner to Enhance Home Energy Systems
- SolarBank’s 3.7 MW Project Aims to Power Local Communities
- Photocat A/S Adjusts Financial Outlook Amid Market Changes
- Transfix Welcomes Uline as Key Customer for Shipper App
- Charles River Associates Announces Q3 2024 Financial Call
- Arianne Phosphate Secures Investment to Boost Production Capacity
- CrateDB Partners with Axcess.io for Enhanced Data Solutions
- Thryv Holdings to Present Key Insights at Analyst Day Event
- O3 Mining Establishes New Marketing and Market-Making Agreements
- Gourmet Jam Vino by Chef Lorious Set to Delight Walmart Shoppers
- Premier, Inc. Prepares to Share Q1 Results and Insights
- SuperCom and Electra Secure New Electronic Monitoring Agreement
- Fast Casual Restaurants Must Balance Speed and Experience
- Transforming Urban Life: Iveda's Smart City Initiatives
- Banxa's Product Innovations and Partnership Growth Update
- State Street's Strategic Growth in Mexico: Expanding Horizons
- Luxand FaceSDK Surpasses Expectations in NIST Testing Results
- LightPath Technologies Set for AUSA 2024 Annual Meeting
- Amazon Pharmacy Expansion: Same-Day Delivery to More Cities
- Discover Novolex's Innovative TamperFlag Food Containers
- Gulf Energy Information Expands Deepwater Conference Advisory Board
- Maximizing Monthly Income: Earning From Wells Fargo Stock
- Tyee Dental Reopens in Modern Space After Unfortunate Fire
- Connectbase Enhances Partnership with PAXIO for Fiber Growth
- E2open Adjusts Outlook as SaaS Revenue Experiences Decline
- National Power Mobilizes Storm Response Teams for Hurricane
- Inclusive Leadership: Shaping the Future Beyond Rhetoric